Last reviewed · How we verify
Antiwei Granules
Antiwei Granules is a Small molecule drug developed by Tasly Pharmaceutical Group Co., Ltd. It is currently in Phase 3 development for Cancer-related conditions (specific indication not publicly detailed).
Antiwei Granules is a traditional Chinese medicine formulation that modulates immune function and inflammatory pathways to support anti-tumor activity.
Antiwei Granules are a small molecule treatment for the common cold, specifically for wind-cold syndrome. They are being studied in a clinical trial (NCT06697886) to evaluate their efficacy and safety in treating this condition.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Antiwei Granules |
|---|---|
| Sponsor | Tasly Pharmaceutical Group Co., Ltd |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Antiwei Granules is a Chinese herbal medicine preparation developed by Tasly Pharmaceutical Group. It is designed to enhance immune function and reduce inflammation through multiple botanical components. The formulation is being investigated in Phase 3 trials, likely for cancer-related indications based on its immunomodulatory properties.
Approved indications
- Cancer-related conditions (specific indication not publicly detailed)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antiwei Granules CI brief — competitive landscape report
- Antiwei Granules updates RSS · CI watch RSS
- Tasly Pharmaceutical Group Co., Ltd portfolio CI
Frequently asked questions about Antiwei Granules
What is Antiwei Granules?
How does Antiwei Granules work?
What is Antiwei Granules used for?
Who makes Antiwei Granules?
What development phase is Antiwei Granules in?
Related
- Manufacturer: Tasly Pharmaceutical Group Co., Ltd — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Cancer-related conditions (specific indication not publicly detailed)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing